Sol-Gel Technologies (SLGL) Competitors $7.38 -0.02 (-0.20%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLGL vs. OKYO, UNCY, PLRX, JSPR, ZURA, EPIX, EXOZ, JMAC, XBIT, and ELUTShould you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include OKYO Pharma (OKYO), Unicycive Therapeutics (UNCY), Pliant Therapeutics (PLRX), Jasper Therapeutics (JSPR), Zura Bio (ZURA), ESSA Pharma (EPIX), eXoZymes (EXOZ), Maxpro Capital Acquisition (JMAC), XBiotech (XBIT), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. Sol-Gel Technologies vs. Its Competitors OKYO Pharma Unicycive Therapeutics Pliant Therapeutics Jasper Therapeutics Zura Bio ESSA Pharma eXoZymes Maxpro Capital Acquisition XBiotech Elutia OKYO Pharma (NASDAQ:OKYO) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations. Do institutionals & insiders have more ownership in OKYO or SLGL? 3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has better valuation and earnings, OKYO or SLGL? Sol-Gel Technologies has higher revenue and earnings than OKYO Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$16.83MN/AN/ASol-Gel Technologies$11.54M1.79-$10.58M-$4.70-1.57 Do analysts rate OKYO or SLGL? OKYO Pharma currently has a consensus price target of $7.00, indicating a potential upside of 176.13%. Sol-Gel Technologies has a consensus price target of $40.00, indicating a potential upside of 441.64%. Given Sol-Gel Technologies' higher probable upside, analysts plainly believe Sol-Gel Technologies is more favorable than OKYO Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Sol-Gel Technologies 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor OKYO or SLGL? In the previous week, Sol-Gel Technologies had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 2 mentions for Sol-Gel Technologies and 1 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.89 beat Sol-Gel Technologies' score of 0.94 indicating that OKYO Pharma is being referred to more favorably in the media. Company Overall Sentiment OKYO Pharma Very Positive Sol-Gel Technologies Positive Which has more volatility & risk, OKYO or SLGL? OKYO Pharma has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Is OKYO or SLGL more profitable? OKYO Pharma has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -107.78%. OKYO Pharma's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A Sol-Gel Technologies -107.78%-43.98%-35.28% SummarySol-Gel Technologies beats OKYO Pharma on 7 of the 11 factors compared between the two stocks. Get Sol-Gel Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLGL vs. The Competition Export to ExcelMetricSol-Gel TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.60M$3.88B$5.54B$8.84BDividend YieldN/A1.20%5.36%4.13%P/E Ratio-1.577.5926.5119.76Price / Sales1.7910.93408.59110.25Price / CashN/A6.4625.8827.49Price / Book0.712.457.935.38Net Income-$10.58M-$109.62M$3.15B$248.34M7 Day Performance1.30%1.12%1.21%1.18%1 Month Performance0.61%9.01%5.51%5.32%1 Year Performance-14.13%36.11%32.65%17.76% Sol-Gel Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLGLSol-Gel Technologies2.6701 of 5 stars$7.39-0.2%$40.00+441.6%-16.9%$20.60M$11.54M-1.5750OKYOOKYO Pharma2.6182 of 5 stars$2.19-7.6%$7.00+219.6%+116.0%$80.19MN/A0.007Gap DownUNCYUnicycive Therapeutics3.1431 of 5 stars$7.11+12.1%$60.00+743.9%-4.8%$80.14M$680K-1.399Trending NewsGap UpHigh Trading VolumePLRXPliant Therapeutics4.1963 of 5 stars$1.25-2.3%$13.31+965.0%-89.2%$78.57M$1.58M-0.3590JSPRJasper Therapeutics2.2454 of 5 stars$5.13-0.4%$62.22+1,112.9%-75.6%$77.36MN/A-0.9820Positive NewsZURAZura Bio3.461 of 5 stars$1.12-0.9%$14.33+1,179.8%-70.0%$77.26MN/A-1.603News CoveragePositive NewsGap DownEPIXESSA Pharma1.9783 of 5 stars$1.72-0.6%$2.00+16.3%-67.7%$76.79MN/A-2.7350EXOZeXoZymesN/A$10.50+14.8%N/AN/A$76.57M$70K0.0029Gap UpHigh Trading VolumeJMACMaxpro Capital AcquisitionN/A$5.70-6.0%N/A+2,986.8%$76.47MN/A0.002,021XBITXBiotech0.6486 of 5 stars$2.59+3.6%N/A-42.2%$76.22M$4.01M-2.01100ELUTElutia3.8795 of 5 stars$1.74-3.9%$8.00+359.8%-60.1%$74.42M$24.38M-0.90180News CoverageGap Down Related Companies and Tools Related Companies OKYO Pharma Alternatives Unicycive Therapeutics Alternatives Pliant Therapeutics Alternatives Jasper Therapeutics Alternatives Zura Bio Alternatives ESSA Pharma Alternatives eXoZymes Alternatives Maxpro Capital Acquisition Alternatives XBiotech Alternatives Elutia Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLGL) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sol-Gel Technologies Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sol-Gel Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
